Bringing the Oncology Community Together

Dr. Nielsen Discusses Using a Ki67 Assay in Breast Cancer

Torsten O. Nielsen, MD, PhD, FRCPC
Published Online: Tuesday, August 13, 2013
Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

A Ki67 assay is cheap, easy, convenient, and gives a physician important information about a patient. Ki67 is a convenient immunohistochemical tool for measuring proliferation, which is a critical factor in breast cancer, though there are some issues with analytical validity. If a physician wants to administer a Ki67 test, he/she must internally validate the test and interpretation, demonstrating analytical validity for the clinical indication in question.

In order to adopt a cut point, one must carefully benchmark an interpretation of Ki67 against existing papers and methods in order to make safe clinical decisions, Nielsen says. Otherwise, there remains a chance of significant bias in an assessment of Ki67, resulting in potentially wrong clinical decisions.

Related Articles
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.